Hagström-Andersson AK

Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in KMT2A-rearranged acute leukemia.

Zhang Q, Falqués-Costa T, Pilheden M, ..., Hyrenius-Wittsten A, Hagström-Andersson AK

Hemasphere 8 (9) e70006 [2024-09-00; online 2024-09-26]

Clinical Genomics [Service] Clinical Genomics Lund [Service]

Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity.

Rodriguez-Zabala M, Ramakrishnan R, Reinbach K, ..., Woods NB, Järås M

Blood Adv 7 (18) 5382-5395 [2023-09-26; online 2023-07-28]

Clinical Genomics [Service] Clinical Genomics Lund [Service] Swedish Metabolomics Centre (SMC) [Service]

FLT3N676K drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis.

Hyrenius-Wittsten A, Pilheden M, Falqués-Costa A, ..., Järås M, Hagström-Andersson AK

Leukemia 33 (9) 2310-2314 [2019-09-00; online 2019-04-05]

Clinical Genomics [Service] Clinical Genomics Lund [Service]